Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.55 |
| ▸ | PNP | P00491 | 1/20 | 0.49 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.44 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.41 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.41 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.41 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | DPP4 | P27487 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Xanthine SCHEMBL29180270 | 0.85 | PNP (0.62) | ALDH1A1PNPGDAGRIA1GRIA2 | |
| SCHEMBL8906319 | 0.78 | ALDH1A1 (0.59) | ALDH1A1SLC2A1PNPGDAGRIA1 | |
| SCHEMBL32689471 | 0.77 | ALDH1A1 (0.57) | ALDH1A1SLC2A1PNPGDAGRIA1 | |
| SCHEMBL5667616 | 0.77 | PNP (0.73) | ALDH1A1SLC2A1PNPGDAGRIA1 | |
| SCHEMBL931969 | 0.77 | ALDH1A1 (0.57) | ALDH1A1SLC2A1PNPGDAGRIA1 | |
| SCHEMBL16513156 | 0.77 | ALDH1A1 (0.57) | ALDH1A1SLC2A1PNPGDAGRIA1 | |
| SCHEMBL932298 | 0.77 | ALDH1A1 (0.57) | ALDH1A1SLC2A1PNPGDAGRIA1 | |
| SCHEMBL10921399 | 0.77 | ALDH1A1 (0.57) | ALDH1A1SLC2A1PNPGDAGRIA1 | |
| SCHEMBL9732084 | 0.77 | ALDH1A1 (0.52) | ALDH1A1SLC2A1PNPGDAGRIA1 | |
| SCHEMBL3757546 | 0.74 | FGFR1 (0.59) | ALDH1A1SLC2A1GRIA1GRIA2GRIA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250289840-A1 | RNA STABILIZING SUBSTANCES AND METHODS OF USE | TEAM MEDICAL, LLC | 2025-09-18 | — | — | US | disclosed |
| EP-1921143-A2 | Mutants of desoxycytidine kinase having extended enzymatic activity | INSTITUT PASTEUR (FR) | 2008-05-14 | — | — | EP | disclosed |
| EP-1383890-B1 | MUTANTS OF DESOXYCYTIDINE KINASE HAVING EXTENDED ENZYMATIC ACTIVITY | PASTEUR INSTITUT (FR) | 2008-05-14 | — | — | EP | disclosed |
| EP-1383890-A2 | MUTANTS OF DESOXYCYTIDINE KINASE HAVING EXTENDED ENZYMATIC ACTIVITY | INSTITUT PASTEUR (FR) | 2004-01-28 | — | — | EP | disclosed |
| WO-2002083892-A2 | MUTANTS OF DESOXYCYTIDINE KINASE HAVING EXTENDED ENZYMATIC ACTIVITY | INSTITUT PASTEUR (FR) | 2002-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250289840-A1 | RNA STABILIZING SUBSTANCES AND METHODS OF USE | SYNCRIP, SNRPA, RNASE1 | ALDH1A1 1153/4885SLC2A1 3963/4885PNP 135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.